Part of UT Health San Antonio

Part of UT Health San Antonio

You are here

Photograph of Devjit Tripathy

Contact

210-567-4852

tripathy@uthscsa.edu

Departments & Divisions

Devjit Tripathy, M.D.

Professor of Medicine

Research

I have been involved in multiple clinical research studies in the pathophysiology of type 2 diabetes. My main focus has been dissecting the underlying mechanisms of insulin resistance and beta cell dysfunction, particularly how elevated free fatty acids induce insulin resistance and the natural history of development of type 2 diabetes as well as pharmacological interventions to prevent type 2 diabetes.   I am currently involved in the validation and mechanism of action of many of the more recent medications used to treat and prevent Type 2 diabetes.  My other field of interest is metabolic effects of sex hormones,  particularly long-term effects of testosterone and estrogen.    Relevant Diseases Diabetes, Insulin resistance, impaired glucose tolerance, hypogonadism, transgender medicine   Techniques Insulin clamps, glucose tolerance test

  • Professional Background

    Education

    • 2005 - Residency - Internal Medicine - State University of NY at Buffalo
    • 2003 - Clinical Fellowship - Endocrinology - State University of NY at Buffalo
    • 2003 - PhD - Endocrinology - Lund University
    • 1996 - MD - Endocrinology - All India Institute of Medical Sciences
    • 1992 - MD - Internal Medicine - Sambalpur University
    • 1989 - MD - SCB Medical College

    Appointments

    • 7/2011 - Associate Professor/ Clinical - University of Texas Health Science Center at San Antonio, Medicine, San Antonio
    • 8/2005 - Staff Physician - Audie L. Murphy VA Hospital, Medicine/Endocrinology, San Antonio
    • 7/2005 - Staff Physician - University Health System, Medicine, San Antonio

  • Instruction & Training

    • 6/2008 - Present, Membership on Supervising Committee, UT Dental School
    • 7/2007 - Present, Mentored clinical endocrinology fellows in clincial research since 2007 -
    • 8/2006 - Present, Post-Doctoral Student Supervision, Audie L Murphy VA Hospital
    • 10/2005 - Present, Post-Doctoral Student Supervision, UHS
    • 7/2005 - Present, Individual Instruction, Audie L Murphy VA Hospital
    • 7/2005 - Present, Diabetes Division Journal club, University of Texas Health Science Center
    • 7/2005 - Present, Endocrinology Case Conference, University of Texas Health Science Center, San Antonio

  • Research & Grants

    Since my initial training days in Endocrinology in India in 1994, I have been pursuing a career in academic medicine. My experience as an endocrinologist for the last 20 years has given me a unique perspective when it comes to recognizing the need for better methods of diagnosis, prevention, and management of Type 2 diabetes. My expertise in the field lies in pathophysiology of T2DM and mechanism of action of newer anti-diabetic medications.

    Grants

    Federal

    Funding Agency NIH Title Regulation of Hepatic and Peripheral Glucose Metabolism Status Active Period 7/2012 - 6/2017 Role Co-Investigator Grant Detail Dr. Ralph DeFronzo is the PI for this study. This study will examine the effect of chronic glucose infusion on insulin signaling in healthy individuals. I am in charge of all the clinical procedures at the BRU, and also the data analysis and eventually will contribute to the publication of the manuscript. The study is currently on going and we expect to complete it by 2016. Funding Agency NIH Title Diabetes effects of long-term implant survival and success. Status Active Period 7/2013 - 5/2017 Role Co-Investigator Grant Detail Dr. Tom Oates is the PI for this project. This project will examine the effect of glycemic control on long-term success of dental implants. I am the endocrinology consultant for this study.

    Private

    Funding Agency Novo Nordisk Title A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events. A multicenter study examining the effect of long-acting Insulin- Insulin Degludec on cardiovascula Status Active Period 6/2014 - 6/2019 Role Co-Investigator Grant Detail A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events. A multicenter study examining the effect of long-acting Insulin- Insulin Degludec on cardiovascular end points in T2DM. Sponsor- Novo- Nordisk. Funding Agency Astra Zeneca Title Exenatide for Cardiovascular Event Trial Status Active Period 3/2012 - 12/2017 Role Principal Investigator Grant Detail A randomized placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with Exenatide once weekly in patients with type 2 Diabetes mellitus. A multicenter study examining the effect of long-acting Exenatide on cardiovascular end points in T2DM.
    Enrollment for this study has been completed and currently 100 patients with T2DM are being followed.

  • Publications

      Abstract

      Jenkinson CP, Tripathy DT, Cromack DT, Curran JE, Kumar S, Carless M, Abdul-Ghani M, Puppala S, Arya R, Dyer TD, Lehman DM, Hu SL, Fourcaudot M, Norton L, Farook VS, Blangero J, Goring HH, DeFronzo RA, Duggirala R. Transcriptomic Identification of ADH1B as a Candidate Gene for Obesity and Insulin Resistance in Human Adipose Tissue in Mexican Americans from the Veterans Administration Genetic Epidemiology Study (VAGES); 2015 Jan. (Diabetes). Chavez A, Vinales K, Mendoza-Guardado R, Alonzo R, Hansis-Diarte A, DeFronzo R, Tripathy D. Differential Effect of Pioglitazone, Exenatide, and Combination of Pioglitazone and Exenatide on Plasma Metabolites in Type 2 Diabetes; 2015 Jan. (Diabetes). Iozzo P, Giuseppe D, Molina-Wilkins M, Ciociaro D, Lancaster J, Triplit C, Cersosimo E, Fx P, Musi N, Tripathy D, Defronzo R, Gastadelli A. A Better Antilipolytic Effect of Insulin and Reduced Adipose Tissue Glucose Uptake after Exenatide Injection during PET-OGTT; 2015 Jan. (Diabetes). Espinoza S, Wnag Chen-Pin, Banerji MA, Bray GA, Buchanan TA, Clement S, Henry RR, Kitabchi A, Mudaliar S, Ratner R, Reaven P, Schwenke D, Stenz F, DeFronzo RA, Tripathy D, Musi N. Pioglitazone Is Equally Effective for Diabetes Prevention in Older Compared with Younger Prediabetic Adults; 2015 Jan. (Diabetes). Daniele G., Perez-Cadena Z., Chavez-Velasquez A., Kamath S., Zuo P., Chang Z., Andreozzi F., Paez A., Fourcaudot M., Winnier D., Hansis-Diarte A., Jenkinson C., Fanti P., Gastaldelli A., DeFronzo R., Tripathy D., Folli F. Low-dose (15 mg/day) pioglitazone treatment improves glycemic and sub-inflammatory state in obese type 2 diabetic subjects in 24 week intervention study; 2012 Jan. (ADA Meeting).

      Book Chapter

      Tripathy D. Is this type 2 diabetes, type 1 diabetes, or late autoimmune diabetes in adults?. In: Tripathy D, Pinkson S, Koops M, DeFronzo RA. Diabetes Case Studies. Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes Association, Diabetes Case Studies 2: American Diabetes Association, Draznin B, Low Wang CC, Rubin DJ, Eds; 2015. p. 64-66.

      Journal Article

      Danielle G, Iozzo P, Molina-Wilkins M, Lancaster J, Ciociaro D, Triplitt C, Cersosimo E, Tripathy D, Fox P, Musi N, DeFronzo RA, Gastaldelli A. Exenatide Affects the Distribution of Cerebral Postprandial Glucose Uptake: (in press) Diabetes 2015 Jan;. Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, McCarren M, Duckworth WC, Emanuele NV; VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes N Engl J Med 2015 Jan;372(23):2197-2206. Tripathy D, Cobb JE, Gall W, Adam KP, Georgete T, Schwenke D, Clement S, Banerji MA, Bray GA, Buchanan TA, Henry RR, Kitabchi A, Mudaliar S, Musi N, Ratner R, Reaven P, Stenz F, and Reaven P, DeFronzo RA. A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACTNOW study. (in press) J Clin Endocrinol Metab 2015 Jan;. Daniele G, Eldor R, Merovci A, Clarke GD, Xiong J, Tripathy D, Taranova A, Abdul-Ghani M, Defronzo RA. Chronic Reduction of Plasma FFA Improves Mitochondrial Function and Whole Body Insulin Sensitivity in Obese and Type 2 Diabetic Individuals Diabetes 2014 Jan;63(8):2812-2820. Tripathy D, Clement S, Schwenke D Banerji MA, Bray GA, Buchanan TA, Henry RR, Kitabchi A, Mudaliar S, Musi N, Ratner R, Reaven P, Stenz F, and Reaven P,. Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW Diabetes Care 2014 Jan;37(6):1706-1711. Tripathy D, Daniele G, Fiorentino TV, Perez-Cadena Z, Chavez-Velasquez A, Kamath S, Fanti P, Jenkinson C, Andreozzi F, Federici M, Gastaldelli A, Defronzo RA, Folli F. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study Diabetologia 2013 Oct;56:2153-2163. Abdul-Ghani MA, Muller FL, Liu Y, Chavez AO, Balas B, Zuo P, Chang Z, Tripathy D, Jani R, Molina-Carrion M, Monroy A, Folli F, Van Remmen H, DeFronzo RA, Abdul-Ghani M. Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance Am J Physiol Endocrinol Metab 2008 Sep;295(3):678-685.

  • Clinical

    Board Certifications

    • American Board of Internal Medicine/Endocrinology
    • American Board of Internal Medicine